Mass spectrometry-based amyloid typing has earned a reputation as the gold standard for identifying the amyloidogenic protein in tissue deposits. By shredding laser-microdissected amyloid plaques into peptides and reading their mass spectra, laboratories can distinguish among more than thirty amyloid types with a specificity that immunohistochemistry and immunofluorescence simply cannot match. Yet the technique has remained confined largely to a handful of reference laboratories because it depends on nanoflow liquid chromatography, in which solvents are pushed through capillaries with inner diameters measured in tens of micrometers. Nanoflow systems deliver exquisite sensitivity, but they come with steep up-front costs, demanding maintenance, long column equilibration times, and a level of operational complexity that deters routine clinical adoption.

The Stanford team, led by Morgan W. Mann and Fangjun Chen with senior authors Megan L. Troxell and Ruben Y. Luo, set out to re-engineer the workflow so that it could run on the high-flow liquid chromatography systems already humming away in hospital laboratories. Their solution rests on two complementary innovations: a sample preparation method called suspension trapping, known commercially as S-Trap, and an acquisition strategy known as data-independent acquisition, or DIA. Together, these techniques allow the analysis of microdissected amyloid plaques using conventional-flow chromatography coupled to tandem mass spectrometry, without sacrificing the diagnostic accuracy that clinicians rely upon.

Suspension trapping is the quieter revolution of the two. In traditional proteomics sample preparation, proteins extracted from tiny tissue fragments must be digested into peptides through a series of solution exchanges, buffer removals, and cleanups that consume time and lose precious material at every step. The S-Trap approach instead traps proteins on a quartz filter matrix as they precipitate out of an acidic methanol-containing buffer. Digestion enzymes then pass through the trap, generating peptides that are eluted in a single, efficient step. The method is fast, robust, and minimizes sample loss, which matters enormously when the starting material consists of a few thousand cells harvested by laser capture microdissection from a formalin-fixed paraffin-embedded tissue section.

Data-independent acquisition addresses the other half of the problem. In classical data-dependent acquisition, the mass spectrometer selects the most intense ions in each scan for fragmentation, a stochastic process that can miss low-abundance peptides and produces data that are tedious to align across runs. DIA, by contrast, fragments all ions within successive wide mass windows, systematically recording fragment spectra for essentially everything in the sample. The resulting data are reconstructed computationally against spectral libraries, yielding consistent and quantitative peptide identifications. Because DIA tolerates the higher flow rates, wider chromatographic peaks, and greater sample loads of high-flow chromatography, it made the leap away from nanoflow feasible rather than merely aspirational.

To translate raw proteomic data into a diagnosis, the researchers also developed a custom selection heuristic that sifts through the hundreds of proteins detected in each plaque and identifies the most likely amyloidogenic culprit. Amyloid deposits are not pure; they sweep up serum proteins, immunoglobulin fragments, and extracellular matrix components as they form. Distinguishing the genuine amyloidogenic protein from innocent bystanders requires weighing total protein abundance, the presence of type-specific signature peptides, and the biological plausibility of each candidate. The heuristic automates this judgment, reducing an expert curation task that could take hours into a reproducible computational step suitable for a busy clinical workflow.

The performance data are striking. Working with laser capture microdissected plaques from 47 patient samples, 10 from cardiac biopsies and 37 from renal biopsies, the team split the material into a training set of 25 samples and an independent testing set of 22. The high-flow LC-DIA-MS/MS method identified the amyloidogenic protein in approximately 96 percent of plaques in both sets, a success rate comparable to established nanoflow approaches. The two inaccuracies observed across the cohort both traced to difficulties in identifying immunoglobulin lambda proteins, once in a specimen obtained after treatment had altered the composition of the deposits and once in a plaque containing two distinct amyloid types simultaneously. These edge cases, the authors note, define the boundaries of the method rather than undermining its general utility.

Reducing the sample preparation workflow to under eight hours carries practical significance beyond convenience. Amyloidosis is increasingly recognized as an urgent diagnosis; cardiac involvement can progress rapidly, and new therapies such as transthyretin stabilizers and silencing agents work best when started early. Every hour shaved from the analytical pipeline shortens the time between biopsy and answer. Equally important, the shift to high-flow chromatography means the method can run on instruments of the kind already deployed for clinical chemistry assays, drug monitoring, and newborn screening in hospital laboratories. That compatibility could transform amyloid typing from a rarefied referral test into an accessible diagnostic performed locally, at lower cost and with faster turnaround.

The study, published in Clinical Proteomics, was conducted on remnant patient specimens under approved institutional review board protocols and funded through the Stanford University Department of Pathology’s Test Development Program, underscoring its explicitly clinical orientation. The authors acknowledge one commercial entanglement: a collaborative research relationship between one investigator and Thermo Fisher Scientific, which provided technical support. While the method will still require validation in other laboratories and across broader panels of amyloid types, the combination of suspension trapping, data-independent acquisition, and high-flow chromatography represents a credible path toward democratizing molecular amyloid typing, offering patients everywhere the prospect of a faster, more precise answer to the question their treatment ultimately depends on.

Subject of Research: A high-flow liquid chromatography-tandem mass spectrometry method for typing amyloidosis in clinical laboratories

Article Title: Suspension trapping and data-independent acquisition enable high-flow liquid chromatography-tandem mass spectrometry-based amyloidosis typing in clinical laboratories

Article References: Mann, M. W., Chen, F., Zhu, C., Lu, C., Liang, B., Kambham, N., Troxell, M. L., & Luo, R. Y. (2026). Suspension trapping and data-independent acquisition enable high-flow liquid chromatography-tandem mass spectrometry-based amyloidosis typing in clinical laboratories. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09628-x

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09628-x

Keywords: amyloidosis, mass spectrometry, proteomics, data-independent acquisition, suspension trapping, liquid chromatography, clinical diagnostics, laser capture microdissection, AL amyloidosis, ATTR amyloidosis, tandem mass spectrometry, clinical proteomics

Childhood and adolescent obesity represents a complex and multidimensional health crisis that has escalated dramatically over recent decades. It is well-established that obesity in youth predisposes individuals to a spectrum of cardiometabolic disorders including insulin resistance, dyslipidemia, hypertension, and eventually type 2 diabetes and cardiovascular disease in adulthood. Yet, the underlying molecular mechanisms linking excess adiposity in young individuals to these downstream health risks have remained elusive. The research conducted by Stinson et al. ventures into this uncharted territory by leveraging advanced proteomic technologies to decode the plasma proteome landscape associated with early cardiometabolic risk.

The research team employed state-of-the-art high-throughput mass spectrometry and multiplex immunoassays to quantitatively profile hundreds of plasma proteins from a diverse cohort of children and adolescents classified as obese based on standard clinical metrics. This approach enabled a comprehensive, unbiased examination of circulating proteins that correlate with established markers of cardiometabolic dysfunction such as insulin sensitivity, inflammatory status, lipid profiles, and vascular health indices. By integrating proteomic data with clinical phenotyping, the investigators were able to pinpoint a distinct panel of plasma proteins whose expression levels not only reflect cardiometabolic perturbations but are also amenable to modification through lifestyle or pharmacological interventions.

Among the identified protein markers, several were linked to pathways of lipid metabolism, inflammatory response, and endothelial function—all critical aspects of cardiometabolic regulation. For example, alterations in apolipoproteins involved in cholesterol transport indicated disruptions in lipid handling that precede clinical dyslipidemia. Concurrently, elevated levels of acute-phase reactants such as C-reactive protein and certain cytokine mediators underscored a state of chronic low-grade inflammation, a hallmark of metabolic syndrome and cardiovascular risk. Intriguingly, proteins associated with nitric oxide synthesis and endothelial nitric oxide synthase activity suggested emerging vascular endothelial dysfunction, an early harbinger of atherosclerosis.

A key strength of this study lies in its emphasis on modifiability, differentiating markers that serve solely as passive indicators of disease from those that may actively participate in pathogenesis and thus represent potential therapeutic targets. The dynamic regulation of the identified proteins by environmental and behavioral factors provides a mechanistic rationale for why early lifestyle interventions—including diet, exercise, and weight management—can effectively alter cardiometabolic trajectories in affected youth. This opens the door for precision medicine approaches that leverage plasma proteomic profiles to tailor individualized prevention programs based on molecular risk signatures rather than solely on phenotypic measurements.

The implications for clinical practice are profound. Current diagnostic frameworks for pediatric cardiometabolic risk rely heavily on anthropometric and biochemical thresholds, which often fail to capture subclinical disease processes or predict long-term outcomes reliably. Incorporating proteomic markers into risk assessment models offers a more nuanced and sensitive toolset for stratifying patients. Early detection of protein abnormalities could drive proactive management decisions, optimize resource allocation, and reduce the incidence of overt disease manifestations during adulthood.

Furthermore, this research underscores the importance of early life as a critical window of opportunity for mitigating cardiometabolic risk. The plasticity of the plasma proteome evidenced in this study suggests that interventions initiated during childhood or adolescence may have amplified benefits in forestalling disease progression. This supports a paradigm shift towards prevention-focused healthcare, emphasizing the monitoring and modulation of molecular markers rather than reactive treatment of complications after they have arisen.

From a mechanistic standpoint, detailed examination of the interplay between identified proteins and known cardiometabolic pathways offers fertile ground for hypothesis generation and drug discovery. Molecules involved in lipid metabolism and inflammatory cascades are already pharmacologic targets in adult populations, but their precise roles and intervention timing in pediatric contexts require elucidation. The potential to repurpose existing therapies or develop next-generation biologics based on these signatures heralds an exciting frontier in pediatric metabolic medicine.

Importantly, the study cohort’s diversity enhances the generalizability and relevance of the findings. Inclusion of participants from varied ethnic and socioeconomic backgrounds captures the heterogeneity of pediatric obesity and its cardiometabolic sequelae, addressing a common limitation in prior research. This inclusivity improves the likelihood that identified markers and associated interventions will be effective across broad populations rather than restricted subsets.

Ethical considerations also arise in deploying proteomic markers in clinical practice. Ensuring equitable access to advanced diagnostic testing and subsequent personalized interventions will require careful policy planning. Additionally, communicating proteomic risk profiles to families must be handled sensitively to avoid undue anxiety while promoting constructive engagement with prevention efforts.

The translational potential of this research is magnified by rapid advancements in proteomics technology, bioinformatics, and systems biology. Integration of the plasma protein signatures with genomic, metabolomic, and microbiome data in future studies promises to deepen comprehension of the multifactorial nature of obesity-related cardiometabolic risk. Such holistic multi-omic approaches could unveil novel biomarker panels with even greater predictive power and therapeutic applicability.

In summary, the identification of modifiable plasma protein markers delineates a transformative path toward precision cardiometabolic health for children and adolescents grappling with obesity. By shifting focus from symptomatic management to molecular risk modulation, this research lays the groundwork for interventions that are timely, targeted, and tailored to individual biological profiles. The ultimate vision is a future where childhood obesity no longer inexorably leads to chronic cardiometabolic disease, but rather, is met with interventions finely tuned to molecular risk landscapes that safeguard lifelong health.

This seminal study not only advances scientific knowledge but also exemplifies how cutting-edge molecular research can be harnessed to address pressing public health challenges. As further investigations validate and expand these findings, the potential to effect meaningful change in pediatric health outcomes becomes increasingly attainable, inspiring hope that the trajectory of childhood obesity and associated cardiometabolic disease can indeed be altered.

Subject of Research: Modifiable plasma protein markers associated with cardiometabolic risk in children and adolescents with obesity.

Article Title: Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity.

Article References:
Stinson, S.E., Huang, Y., Thielemann, R. et al. Identification of modifiable plasma protein markers of cardiometabolic risk in children and adolescents with obesity. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68415-2

Image Credits: AI Generated